Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Articles|November 1, 2006
- Applied Clinical Trials-11-01-2006
- Volume 0
- Issue 0
Merging eHR & EDC Conference
Photo highlights from ExL Pharma's September Conference: Merging eHR & EDC.
Advertisement
Participants from the pharmaceutical industry, HIT, EDC, NIH, and academia gathered in Washington, DC in September to explore, discuss, debate, and resolve present issues confronting and challenging the use of electronic health records (eHR) and electronic data capture (EDC) in clinical research.
Day One of ExL Pharma's "Merging eHR & EDC" Conference began with a hearty discussion of whether eHR and EDC can be merged. The discussion flowed well into Day Two's presentations on practical approaches to implementation and convergence.
Articles in this issue
about 20 years ago
Building Your Clinical IT Teamabout 20 years ago
Tough Trials Ahead for Europe's Drug Industryabout 20 years ago
Experts Urge Major Overhaul at FDAabout 20 years ago
Recruitment & Consent in Indiaabout 20 years ago
eShowcase: iPlan Flowabout 20 years ago
Pharmacogenomics Enters the Japanese Marketabout 20 years ago
Meet the EAB: Somesh Nigamabout 20 years ago
Deploying Mobile Devices in Clinical Trials: Part Twoabout 20 years ago
eShowcase: Clintrace 4.1about 20 years ago
eShowcase: PharmaReady V3.0Advertisement
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
3
What Needs to Happen Beyond the Clinical Trial Modernization Act
4
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
5